Skip Nav Destination
Article navigation
Volume 8, Issue 10
1 October 2018
-
Abstract
Research Watch| October 02 2018
Author & Article Information
Online ISSN: 2159-8290
Print ISSN: 2159-8274
©2018 American Association for Cancer Research.
2018
American Association for Cancer Research.
Cancer Discov (2018) 8 (10): 1208.
- Split-Screen
- Views Icon Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
- Peer Review
- Open the PDF for in another window
- Tools Icon Tools
Cite Icon Cite
- Search Site
- Article Versions Icon Versions
- Version of Record October 2 2018
- Proof August 31 2018
Citation
An S/G2 Checkpoint Regulated by ATR Preserves Genome Integrity. Cancer Discov 1 October 2018; 8 (10): 1208. https://doi.org/10.1158/2159-8290.CD-RW2018-150
Download citation file:
- Ris (Zotero)
- Reference Manager
- EasyBib
- Bookends
- Mendeley
- Papers
- EndNote
- RefWorks
- BibTex
Abstract
Cells possesses an ATR-enforced intrinsic checkpoint controlling the S/G2 transition.
Major finding: Cells possesses an ATR-enforced intrinsic checkpoint controlling the S/G2 transition.
Concept: The S/G2 transition is marked by a switch-like phosphorylation of FOXM1 to initiate the mitotic program.
Impact: Regulation of the S/G2 transition by ATR promotes genome integrity.
Progression through the cell cycle is tightly regulated by a series of regulatory checkpoints. The G1/S, G2/M, and metaphase/anaphase transition checkpoints have been well characterized, but a checkpoint controlling the S/G2 transition has not been identified. DNA damage can activate the checkpoint kinase ATR to arrest cells in the S or G2 phase and ensure complete replication before mitosis, prompting Saldivar and colleagues to hypothesize that ATR may regulate the S/G2 transition. Inhibiting ATR in S phase accelerated mitotic entry, but ATR inhibition did not accelerate mitotic entry in G2 cells, suggesting that ATR acts in S phase to delay mitosis. However, S-phase shortening was not sufficient to explain the combined shortening of S and G2, and it was determined that, in addition to the role in S phase, ATR controlled accumulation of promitotic factors to regulate G2 duration. ATR inhibition resulted in premature accumulation of cyclin B in S phase as well as other promitotic factors, indicating that ATR suppresses transcription of G2/M genes poised for activation during S phase. Analysis of publicly available chromatin immunoprecipitation sequencing data revealed that the transcription factor FOXM1, which is frequently overexpressed in cancer, was enriched at the promitotic genes and drove premature expression of cyclin B. Inhibiting ATR in early S phase led to hyperphosphorylation of FOXM1, resulting in premature FOXM1 activation and early mitosis. Mechanistically, FOXM1 was phosphorylated by CDK1 at the S/G2 transition, and this phosphorylation switch facilitated G2 entry. In contrast, during normal DNA replication, ATR was activated by ETAA1, and prevented CDK1-dependent FOXM1 phosphorylation until G2. Thus, ATR inhibition deregulated the S/G2 transition to promote early mitosis, leading to underreplicated DNA and DNA damage. Collectively, these findings uncover an S/G2 checkpoint regulated by ATR that is responsible for maintaining genome integrity. As ATR inhibitors are being tested in cancer clinical studies, this finding could shed light on strategies to improve the efficacy of ATR inhibitors in the clinic.
Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.
©2018 American Association for Cancer Research.
2018
American Association for Cancer Research.
411 Views
View Metrics
Citing articles via
Google Scholar
Advertisem*nt
Email alerts
Article Activity Alert
Online First Alert
eTOC Alert
Close Modal
Breaking
Don’t Rechallenge with an ICI in Renal Cell Carcinoma
Subcutaneous PD-1 Injection Potential Boon for Patients
Mammogram Reports Must Now Specify Breast Density
View more recent articles
Latest News
Short-Term Exposure to Air Pollution May Drive Lung Cancer in Never-Smokers
Insufficient Genetic Data Forbode Trial Stoppages
Evidence Points to the Value of Neoadjuvant Therapy for NSCLC
View more recent articles
Research Watch
Post-Fast Refeeding Drives Stem Cell Regeneration via Polyamine Metabolism
The Fanconi Anemia Pathway Mediates Chromothripsis and Resistance to Cancer Therapy
X Chromosome Translocations Drive Sex Bias in a Rare Kidney Cancer Subtype
View more recent articles
- Latest
- Most Read
- Most Cited
Trem2-expressing multinucleated giant macrophages are a biomarker of good prognosis in head and neck squamous cell carcinoma
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
Increased RNA and protein degradation is required for counteracting transcriptional burden and proteotoxic stress in human aneuploid cells